🔗 Share this article

Given that America continues making unprecedented revisions to its immunization guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus vaccines throughout the pandemic and has focused upon alleged deaths after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Health officials were set to announce radical changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of step with much of the international standard with no evidence for public health gain. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Høeg is set to speak at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this year.

Consolidating Power at the Agency

This interim role might represent a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for halting certain pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a society with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – traditionally the purview of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible experience in drug development, approval processes or administrative roles, which has been standard for previous directors of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of the center would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who headed the center have had.”

CDER has an enormous portfolio at the agency, Woodcock emphasized.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those have to be supervised,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the role, which manages in excess of 5,000 staff members. “It’s a massive management job, if you do it right,” Woodcock concluded.

Official Statement and Controversial Policies

Regarding questions about Høeg’s qualifications and whether this appointment represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns are based on flawed presumptions”.

“Her experience is consistent with the responsibilities of her role,” the official said, citing the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a disputed rapid therapy clearance system that reportedly concerned her preceding directors. “By what process are these medications being picked for this fast-track system? Who is making the decisions?” Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards more relaxed oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more documented, if concerning, past, some experts observe. She released a analysis using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are more dangerous than they are.

Among her “wish list” for the incoming government included altering guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked following the vote on a online show. At the FDA, Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccines.

“She is an complete ideologue who begins with her beliefs and reverse-engineers to fit the data in a highly misleading, untruthful manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|